Exelixis Earnings: What Investors Should Watch

Exelixis (NASDAQ:EXEL) will report earnings after markets close on Tuesday, May 7th. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Here is your Cheat Sheet to Exelixis Earnings:

Earnings Expectations: Analysts expect earnings of $-0.28 per share on revenues of $5.33 million.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.27 to a loss $0.3. For the current year, the average estimate is a loss of $1.24, which is worse than the estimate ninety days ago.

The stock market is at 5-year highs! Discover the best stocks to buy in today’s market. CLICK HERE for Your Stock Investor Cheat Sheet NOW!

Earnings Trends:

Here’s how Exelixis has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 117.86 151.76 185.04 289.64 47.45
Diluted EPS ($) -1.54 -1.26 -0.85 0.58 -0.92

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 93.31 18.51 7.81 13.31 7.81
Diluted EPS ($) 0.3460 -0.18 -0.25 -0.20 -0.2843

Past Performance:
Exelixis has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)